NewAmsterdam Pharma N.V. (NAMS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    NewAmsterdam Pharma N.V.

    NASDAQ: NAMS · Real-Time Price · USD
    28.50
    2.21 (8.41%)
    At close: Sep 26, 2025, 3:59 PM
    29.00
    1.75%
    After-hours: Sep 26, 2025, 07:27 PM EDT

    NewAmsterdam Pharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 45.56M 12.76M 95.91M n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 45.56M 12.76M 95.91M n/a
    Operating Income
    		 -176.29M -165.73M -3.32M -30.73M
    Interest Income
    		 16.88M 10.22M 268.03K 361.1K
    Pretax Income
    		 -241.6M -160.25M -21.14M -36.71M
    Net Income
    		 -241.6M -176.94M -21.14M -36.71M
    Selling & General & Admin
    		 70.45M 29.77M 18.22M 5.27M
    Research & Development
    		 151.41M 159.42M 81.01M 25.46M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 221.85M 197.06M 116.78M 36.35M
    Interest Expense
    		 n/a 6.8M n/a n/a
    Selling & Marketing Expenses
    		 n/a 4.06M 1.6M 858.39K
    Cost & Expenses
    		 221.85M 183.23M 116.78M 36.35M
    Income Tax Expense
    		 -1K 27K n/a n/a
    Shares Outstanding (Basic)
    		 94.36M 82.16M 18.97M 17.75M
    Shares Outstanding (Diluted)
    		 94.36M 82.16M 18.97M 17.75M
    EPS (Basic)
    		 -2.56 -2.15 -1.11 -3.34
    EPS (Diluted)
    		 -2.56 -2.15 -1.11 -3.34
    EBITDA
    		 -241.49M -176.86M -3.31M -30.73M
    EBIT
    		 -241.6M -176.91M -22.35M -30.73M
    Depreciation & Amortization
    		 113K 49K 8.4K 4.39K

    Add to Watchlist